Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Business Review
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim's DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
pharminent
April 16, 2026 (Last updated: April 16, 2026)
Pharmaceutical Business Review
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
